Vol. 121, No. 1 (Supplement) 2016
Supplement abstract

The role of MICAL2 gene in myogenic differentiation

Published 2017-10-06


  • Myogenic differentiation,
  • MICAL2,
  • stem cells

How to Cite

Giarratana, N., Tamburro, O., Benedetti, L., Angeloni, D., De Angelis, M. G. C., Ceccarelli, G., & Sampaolesi, M. (2017). The role of MICAL2 gene in myogenic differentiation. Italian Journal of Anatomy and Embryology, 121(1), 85. Retrieved from https://oajournals.fupress.net/index.php/ijae/article/view/2223


The dystrophin-glycoprotein complex (DGC) is composed of several transmembrane and peripheral components localized in the sarcolemma of skeletal muscle. Mutations in genes that encode DGC components lead to the loss of either expression and/or function of the DGC in muscle. As DGC complex interacts with F-actin it is reasonable that the multidomain F-actin binding protein MICAL2 that transduces semaphorin/plexin external signaling into cytoskeletal modifications, might interact either directly or indirectly with the DGC complex. MICAL2 is indeed expressed in skeletal and cardiac muscles and drosophila Mical mutants reveal that the architecture of contractile muscle filaments is negatively affected. We focus here on the role of MICALs in myogenic differentiation. The rationale to investigate MICAL2 in muscle differentiation is also highlighted in a paper regarding a complex muscle genome-wide expression profiling during the disease evolution in mdx mice, a mouse model of Duchenne muscular dystrophy (1). In this study the authors found MICAL2 among a set of totally ten functionally linked genes involved in the decline of muscle necrosis in mdx mice. For this purpose MICAL2 gain and loss of function studies have been performed in myogenic cell line and compared to in vivo analysis of MICAL2 expressions in acute and chronic muscle degeneration. Recently we showed that that differential myogenic propensity influences the commitment of isogenic induce pluripotent stem cells and a specifically isolated pool of mesodermal iPSC-derived progenitors (MiPs) toward the striated muscle lineages (2). Analysis of MICAL2 expression in MiPs is currently under investigation. Taken together modulation of MICAL2 has an impact on skeletal muscle commitment and could be considered a potential therapeutic target for Duchenne patients. This work was supported with the contribution of “Opening The Future” Campaign [EJJ-OPTFUT-02010] CARIPLO 2015_0634, FWO (#G088715N, #G060612N, #G0A8813N), and IUAP-VII/07 (EJJ-C4851-17/07-P) grants.